Skip to main content
German

Indications, multiplied.

Introducing HFX for PDN

The SCS system approved by the FDA with a specific indication for Painful Diabetic Neuropathy.

Connect with a Local Representative

Meaningful Evidence

Nevro’s unique PDN indication is the outgrowth of years of investments in clinical trials culminating with the SENZA-PDN, the largest RCT evaluating SCS for PDN to date.

JAMA Neurology

Meaningful Evidence

Diabetes Care

Meaningful Evidence

JDST RWE

Meaningful Evidence

JDST Review of Evidence

Meaningful Evidence
10 KHz outcomes at 12 months

Excellent Safety and
Efficacy Profile

Within the SENZA-PDN, 10 kHz Therapy
demonstrated exceptional outcomes across
responder rates, pain relief, and even
sensory response.

Uniquely Possible
With 10 kHz Therapy

Historically, PDN patients have struggled with a
lack of treatment options when CMM fails.
Now, 10 kHz Therapy and a unique mechanism
of action offer new potential for relief.

LEARN ABOUT THE UNIQUE MOA

Direct Neural Inhibition With
10 kHz Therapy

Uniquely Possible With 10 kHz Therapy